NCT05631990View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AD-209

PHASE2CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

April 5, 2023

Primary Completion Date

November 27, 2023

Study Completion Date

November 27, 2023

Conditions
Hypertension, Essential
Interventions
DRUG

AD-209

PO, Once daily(QD), 8weeks

DRUG

AD-209-1A

PO, Once daily(QD), 8weeks

DRUG

AD-209-1B

PO, Once daily(QD), 8weeks

DRUG

AD-209-1C

PO, Once daily(QD), 8weeks

DRUG

AD-209 placebo

PO, Once daily(QD), 8weeks

DRUG

AD-209-1 placebo

PO, Once daily(QD), 8weeks

Trial Locations (1)

Unknown

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT05631990 - A Study to Evaluate the Efficacy and Safety of AD-209 | Biotech Hunter | Biotech Hunter